Genome editing in the adrenal gland: a novel strategy for treating congenital adrenal hyperplasia
Eva B. van Dijk , Samantha L. Ginn , Ian E. Alexander , Lara E. Graves
Exploration of Endocrine and Metabolic Diseases ›› 2024, Vol. 1 ›› Issue (3) : 101 -21.
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency leads to high morbidity and mortality, despite the availability of life-saving corticosteroid replacement therapy. Gene therapy represents a promising potential treatment for monogenic disorders such as congenital adrenal hyperplasia, overcoming the limitations of corticosteroid replacement approaches. Adeno-associated viral vectors are currently the leading vector for direct in vivo gene delivery. However, physiological properties of the adrenal gland limit the application of adeno-associated viral vector-based gene addition strategies. To achieve durable correction in the adrenal gland, gene editing must be employed to stably introduce a genetic modification into the CYP21A2 locus. The safety of this and other gene editing approaches could be greatly improved by using lipid nanoparticles for the delivery of editing machinery mRNA. While little data exists regarding adrenocortical lipid nanoparticle targeting, physiological features of this organ (such as high relative blood flow, fenestrated endothelium, and cholesterol uptake) indicate the promise of these delivery vectors for the treatment of monogenic diseases of the adrenal cortex. This review discusses the complexities of developing gene therapy for congenital adrenal hyperplasia and explores the viability of novel gene therapy strategies in this application.
Gene editing / congenital adrenal hyperplasia / lipid nanoparticles / vectors / adeno-associated virus / mRNA therapeutics / CRISPR/Cas9
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
Grabek A, Dolfi B, Klein B, Jian-Motamedi F, |
| [8] |
|
| [9] |
Buchlis G, |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
Musunuru K, |
| [15] |
Assessment report: Onpattro [Internet]. London: European Medicines Agency; c2018 [cited 2024 Jan 21]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/onpattro-epar-public-assessment-report_en.pdf |
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
Bertagna X. Effects of chronic ACTH excess on human adrenal cortex. Front Endocrinol (Lausanne). 2017; 8: 43. |
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
Falhammar H, Nordenström A. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome. Endocrine. 2015; 50: 32-50. |
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
Gene, cell, & RNA therapy landscape Q2 2021 quarterly data report [Internet]. Waukesha: American Society of Gene + Cell Therapy; [cited 2024 Jan 21]. Available from: https://www.asgct.org/global/documents/asgct-pharma-intelligence-quarterly-report-july-20.aspx |
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
CAH letter to community Q1 2023 [Internet]. Raleigh: Adrenas Therapeutics; [cited 2024 Jan 21]. Available from: https://adrenastx.com/wp-content/uploads/CAH-Letter-to-Community-Q1-2023-Update-FINAL.pdf |
| [69] |
ADventure trial update [Internet]. Raleigh: Adrenas Therapeutics; [cited 2024 Jan 21]. Available from: https://cahgenetherapy.com/news/jan24 |
| [70] |
White PC. Emerging treatment for congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes. 2022; 29: 271-6. |
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
Iannaccone P, Morley S, Skimina T, Mullins J, Landini G. Cord-like mosaic patches in the adrenal cortex are fractal: implications for growth and development. FASEB J. 2003; 17: 41-3. |
| [76] |
|
| [77] |
Zwemer RL. A study of adrenal cortex morphology. Am J Pathol. 1936; 12: 107-14. |
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010; 79: 181-211. |
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
Suzuki K, Tsunekawa Y, Hernandez-Benitez R, Wu J, Zhu J, Kim EJ, |
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
Mukai H, Ogawa K, Kato N, |
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
Kis Z, Kontoravdi C, Shattock R, Shah N. Resources, production scales and time required for producing RNA vaccines for the global pandemic demand. Vaccines (Basel). 2020; 9: 3. |
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
Uhlén M, Fagerberg L, |
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
/
| 〈 |
|
〉 |